IPOS photocopied.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

9900326-1

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 215/48, A61K 31/47

A1

(11) International Publication Number: WO 98/07704

(43) International Publication Date: 26 February 1998 (26.02.98)

(21) International Application Number: PCT/EP97/04440

(22) International Filing Date: 14 August 1997 (14.08.97)

(30) Priority Data:
9617305.9 17 August 1996 (17.08.96) GB

(71) Applicant *(for all designated States except US)*: GLAXO WELLCOME S.P.A. [IT/IT]; Via Alessandro Fleming, 2, I-37100 Verona (IT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: DI-FABIO, Romano [IT/IT]; Glaxo Wellcome S.p.A., Via Alessandro Fleming, 2, I-37100 Verona (IT). PASQUARELLO, Alessandra [IT/IT]; Glaxo Wellcome S.p.A., Via Alessandro Fleming, 2, I-37100 Verona (IT). SABBATINI, Fabio, Maria [IT/IT]; Glaxo Wellcome S.p.A., Via Alessandro Fleming, 2, I-37100 Verona (IT).

(74) Agent: FILLER, Wendy, Anne; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published


With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: TETRAHYDROQUINOLINE DERIVATIVES AS EAA ANTAGONISTS

(57) Abstract

Compounds of formula (I) or a salt, or metabolically labile ester thereof wherein R represents a group selected from halogen, alkyl, alkoxy, amino, alkylamino, dialkylamino, hydroxy, trifluoromethyl, trifluoromethoxy, nitro, cyano, SO_2R_2 or COR_2 wherein R_2 represents hydroxy, methoxy, amino, alkylamino or dialkylamino; m is zero or an integer 1 or 2; R_1 represents a group $(CH_2)nCN$, $-CH=CHR_3$, $(CH_2)nNHCOCH_2R_4$ or $O(CH_2)pNR_5R_6$; R_3 represents cyano or the group COR_7; R_4 represents alkoxy or a group $NHCOR_8$; R_5 and R_6 each represent independently hydrogen or alkyl, or R_5 and R_6 together with the nitrogen atom to which they are attached represent a heterocyclic group, or R_5 is hydrogen and R_6 is the group COR_9; R_7 represents an alkoxy, amino or hydroxyl group; R_8 represents a hydrogen atom or optionally substituted alkyl, alkoxy, aryl or heterocyclic group; R_9 is the group R_8 or the group $NR_{10}R_{11}$ wherein R_{10} represents hydrogen or alkyl group; R_{11} represents optionally substituted alkyl, aryl, heterocyclic or cycloalkyl group; n is zero or an integer from 1 to 4; p is an integer from 2 to 4, processes for their preparation and to their use in medicine.



(I)